Abeona Therapeutics logo

Abeona TherapeuticsNASDAQ: ABEO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 September 1980

Next earnings report:

18 March 2025

Last dividends:

N/A

Next dividends:

N/A
$249.09 M
-14%vs. 3y high
57%vs. sector
-vs. 3y high
-vs. sector
-66%vs. 3y high
83%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 21:49:51 GMT
$5.73-$0.16(-2.72%)

Dividend

No data over the past 3 years
$125.00 K$83.33 K

Analysts recommendations

Institutional Ownership

ABEO Latest News

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
globenewswire.com14 November 2024 Sentiment: POSITIVE

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
globenewswire.com12 November 2024 Sentiment: POSITIVE

CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Abeona's resubmission of its Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025.

Abeona Therapeutics® Announces Participation in November Investor Conferences
globenewswire.com04 November 2024 Sentiment: POSITIVE

CLEVELAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2024:

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy
seekingalpha.com03 October 2024 Sentiment: POSITIVE

Abeona Therapeutics' Pz-cel, a gene-corrected cell therapy for RDEB, is expected to resubmit its BLA in 2H2024, targeting FDA approval by mid-2025. ABEO's AIM platform uses AAV vectors for targeted genetic material delivery, with a pipeline including therapies for genetic eye conditions and neurological diseases. Pz-cel offers long-lasting treatment for RDEB, addressing a substantial total addressable market.

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
globenewswire.com03 September 2024 Sentiment: POSITIVE

CLEVELAND, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2024:

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
globenewswire.com12 August 2024 Sentiment: POSITIVE

Significant progress addressing CMC items noted in CRL BLA resubmission remains on track for 2H 2024 CLEVELAND, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2024 and recent corporate progress. “Having completed data generation for nearly all of the Chemistry Manufacturing and Controls deliverables outlined in the Complete Response Letter that we received in April 2024, we are on track to resubmit our Biologics License Application for pz-cel this year and, if approved, bring a treatment option to patients with recessive dystrophic epidermolysis bullosa,” said Vish Seshadri, Chief Executive Officer of Abeona.

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
globenewswire.com11 July 2024 Sentiment: POSITIVE

CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced an agreement by which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications.

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
globenewswire.com08 July 2024 Sentiment: POSITIVE

CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Stifel Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 9:45 a.m. Eastern Time.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
prnewswire.com07 June 2024 Sentiment: NEGATIVE

NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
globenewswire.com05 June 2024 Sentiment: NEGATIVE

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

  • 1(current)

What type of business is Abeona Therapeutics?

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

What sector is Abeona Therapeutics in?

Abeona Therapeutics is in the Healthcare sector

What industry is Abeona Therapeutics in?

Abeona Therapeutics is in the Biotechnology industry

What country is Abeona Therapeutics from?

Abeona Therapeutics is headquartered in United States

When did Abeona Therapeutics go public?

Abeona Therapeutics initial public offering (IPO) was on 19 September 1980

What is Abeona Therapeutics website?

https://www.abeonatherapeutics.com

Is Abeona Therapeutics in the S&P 500?

No, Abeona Therapeutics is not included in the S&P 500 index

Is Abeona Therapeutics in the NASDAQ 100?

No, Abeona Therapeutics is not included in the NASDAQ 100 index

Is Abeona Therapeutics in the Dow Jones?

No, Abeona Therapeutics is not included in the Dow Jones index

When was Abeona Therapeutics the previous earnings report?

No data

When does Abeona Therapeutics earnings report?

The next expected earnings date for Abeona Therapeutics is 18 March 2025